tbuckley/cabot-search huggingface dataset:
Below-Knee Amputations in Patients With Severe Arterial Insufficiency
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Research in Cystic Fibrosis
Authors: Paul A. di Sant'Agnese, Pamela B. Davis
Journal: New England Journal of Medicine (1976)

CYSTIC fibrosis is the most common lethal or semi-lethal genetic disease of peoples of Caucasian descent and is transmitted as an autosomal recessive trait. It affects primarily the exocrine glands, but although mucus-secreting ones are involved pathologically, the serous glands (e.g., eccrine sweat and parotid glands) have no histologic changes, even though their secretions may be abnormal chemically.Clinically, cystic fibrosis is characterized by the triad of chronic pulmonary disease, pancreatic insufficiency and elevated sweat electrolytes. Many other clinical manifestations may be present and complicate the clinical picture. The homozygotes have all, or substantially all, manifestations . . .
The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity
Authors: Benoit Viollet, Fabrizio Andreelli, Sebastian B. Jørgensen, Christophe Perrin, Alain Geloen, Daisy Flamez, James Mu, Claudia Lenzner, Olivier Baud, Myriam Bennoun, Emmanuel Gomas, Gaël Nicolas, Jørgen F.P. Wojtaszewski, Axel Kahn, David Carling, Frans C. Schuit, Morris J. Birnbaum, Erik A. Richter, Rémy Burcelin, Sophie Vaulont
Journal: Journal of Clinical Investigation (2003)

AMP-activated protein kinase (AMPK) is viewed as a fuel sensor for glucose and lipid metabolism. To better understand the physiological role of AMPK, we generated a knockout mouse model in which the AMPKα2 catalytic subunit gene was inactivated. AMPKα2–/– mice presented high glucose levels in the fed period and during an oral glucose challenge associated with low insulin plasma levels. However, in isolated AMPKα2–/– pancreatic islets, glucose- and L-arginine–stimulated insulin secretion were not affected. AMPKα2–/– mice have reduced insulin-stimulated whole-body glucose utilization and muscle glycogen synthesis rates assessed in vivo by the hyperinsulinemic euglycemic clamp technique. Surprisingly, both parameters were not altered in mice expressing a dominant-negative mutant of AMPK in skeletal muscle. Furthermore, glucose transport was normal in incubated isolated AMPKα2–/– muscles. These data indicate that AMPKα2 in tissues other than skeletal muscles regulates insulin action. Concordantly, we found an increased daily urinary catecholamine excretion in AMPKα2–/– mice, suggesting altered function of the autonomic nervous system that could explain both the impaired insulin secretion and insulin sensitivity observed in vivo. Therefore, extramuscular AMPKα2 catalytic subunit is important for whole-body insulin action in vivo, probably through modulation of sympathetic nervous activity.
Hispanic health: time for data, time for action
Authors: A. C. Novello
Journal: JAMA (1991)

It is the nature of health statistics to remind us of who we are. Be it information on morbidity, disability, or mortality, the power of health-related data lies in its unblinking capacity to reflect the currents of daily life and their roots in common origins and social ties. It is not surprising, therefore, that the analysis of health data is often conducted in terms of broad perceptions of ethnicity and race. This issue ofThe Journalbreaks new ground in addressing the health issues of Hispanic communities in the United States. Currently the second largest minority group in the United States, the 20 million Hispanics represent an estimated 8.2% of the total population reported to the US Census Bureau in 1989. If current trends continue, Hispanics will represent the largest minority population in the United States by the early 21st century. If nothing else, the collection of articles in this
Fiber Optics in Medicine
Authors: John A. Goldman, Sandy Bereskin, Carolyn Shackney
Journal: New England Journal of Medicine (1965)

IF one end of a dielectric cylinder such as a glass rod or fiber is illuminated, much of the light will be trapped inside and transmitted by multiple internal reflections even around curves to the other end. This phenomenon was first demonstrated in 1870 by the British physicist, John Tyndall. His light conductor was a stream of water pouring from a hole in the side of a tank. When he shone light into the top of the tank the beam emerged through the hole and followed the path of the water curving downward.No one knows who first discovered that . . .
Errata
Journal: JNCI Journal of the National Cancer Institute (1961)

In the articles “Some Peculiar Biological and Biochemical Properties of a Mouse Hepatoma Induced by Chyrosidin. I, II, and III” by Zygmunt Albert and Marian Orłowski, chrysoidin should be spelled chrysoidine. It was incorrectly referred to as 2,4′-azodianiline instead of 2,4-diaminoazobenzene or 4-phenylazo-m-phenylenediamine.
Traveling Clinic Provides Diagnostic Help for Mentally Retarded Children
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer of the urogenital tract: Wilms' tumor and neuroblastoma. Neuroblastoma
Authors: P. Rubin
Journal: JAMA (1968)

The term "neuroblastoma" is an umbrella covering a variety of histologic types of tumor which arise from cells in the neural crest to form the sympathetic ganglia and the adrenal medulla. The primitive cell is the sympathicogonioma and differentiates along two lines as shown in the modified diagram by Karsner<sup>1</sup>(Introductory Figure). This series of communications is concerned with those tumors of sympathetic nervous tissue origin: sympathicogonioma, sympathicoblastoma, and ganglioneuroma. It is important to note that the more malignant tumor which tends to arise in the infant and younger child is the sympathicogonioma; the sympathicoblastoma is more highly differentiated and less malignant when it occurs in later life. The ganglioneuroma is usually a benign tumor; it tends to occur in older children (over 10 years of age) and rarely metastasizes. The key to understanding the changing attitude toward treatment in this malignancy lies in the evolution of the highly
The Cover
Authors: Mark S. Litwin
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stagnant Numbers of Uninsured
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The clinical recognition of botulism
Authors: K. E. Nelson
Journal: JAMA (1979)

In this issue ofThe Journal(p 475), Terranova and colleagues describe the ocular and neurologic findings in a group of 59 persons involved in a common-source outbreak of type B botulism. This is the largest outbreak of botulism yet reported in the United States, and it afforded an opportunity for the prospective and systematic observation of the evolving signs and symptoms of the disease. In this outbreak all affected persons noted a dry mouth, and 51 (86%) had difficulty focusing to a near point or had diplopia before they visited a physician. Bilateral abducens nerve palsy developed in nearly all persons. Signs of bilateral severe third cranial nerve palsy were of prognostic importance. Among 11 persons in whom all three signs of third nerve palsy-medial rectus palsy, ptosis, and sluggishly reacting pupils developed, eight subsequently had respiratory insufficiency. Noteworthy respiratory insufficiency subsequently developed in only one patient without all
The Examination of the Function of the Intestines by Means of the Test Diet.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
UNSUCCESSFUL TREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PREPARATIONS OF TIN
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dear
Authors: Doris L. Clowney
Journal: JAMA (1983)

<h3>To the Editor.—</h3> I was pleased with Dr Calmes' opinion in A PIECE OF MY MIND. I, too, take exception to the common use of the term<i>dear</i>when addressing female patients as well as to addressing patients by their first names. As a black woman, I have long been aware of the "demeaning" and disrespectful nature of this practice. I have stayed with my childhood training in addressing older acquaintances by title and last name. This practice also extends to all my patients except the very young (early teens and younger). I agree that "changes must be made." Terms of endearment should be reserved for personal greetings between friends, not exchanges between patients and medical professionals.
Popular Physiology.
Authors: A. H. SCOFIELD
Journal: JAMA (1898)

Ryan, Iowa, June 17, 1898. <h3>To the Editor:</h3> —The following clipping from the Lincoln (Neb.)<i>Journal</i>is a rather peculiar specimen of popular physiology: "The windpipe was partially severed, and the sufferer could only breathe by dropping his chin close to his throat. Otherwise the air escaped through the gash instead of going into the lungs." Sincerely yours,
Taking blood from the ear lobe is less painful than from the thumb
Journal: BMJ (2000)

Cardioprotective value of aspirin in primary prevention is greater the lower the blood pressure In primary prevention, middle aged men at increased risk of coronary heart disease seem to benefit more from aspirin when systolic blood pressure is lower.The use of aspirin, often self prescribed, in those who have so far not experienced heart attacks requires careful consideration as only a few episodes will be prevented and even low doses of aspirin may carry an appreciable risk of potentially serious bleeding.The US physicians trial suggested that older men and those with low cholesterol concentrations would benefit most, but the UK thrombosis prevention trial (p 13) does not confirm these suggestions.The UK trial in 5499 men treated over nearly seven years showed that the risk of heart attacks was reduced by about half in those with lower blood pressures whereas there was little if any effect in those with higher pressures.These findings need to be confirmed or refuted, however, before they are taken as firm evidence in clinical practice.No link exists between blood transfusion and sporadic CJD
THE PRODUCTION OF ACID BY THE GROWTH OF PNEUMOCOCCI IN PNEUMONIC SERUM.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Natural History of the Child.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients pretreated with bevacizumab.
Authors: Alberto F. Sobrero, Roberto Bordonaro, Katia Bencardino, Filippo Pietrantonio, Stefan Bauer, Julien Taïeb, Pascale Garreau-Laporte, Chiara Zilocchi, Emmanuelle Dochy, Gérard Lledo
Journal: Journal of Clinical Oncology (2015)

e14686 Background: In the VELOUR study, adding ziv-aflibercept (Z) (known as aflibercept outside the United States) to FOLFIRI resulted in improved OS, PFS, and RR in metastatic colorectal cancer (mCRC) patients (pts) who had received prior oxaliplatin. Prior treatment with bevacizumab (B) did not appear to impact safety profile of Z. The global ASQoP/AFEQT studies are 2 clinical studies (ASQoP [NCT01571284]; AFEQT [NCT01670721]) designed to capture QoL and safety data from a population similar to VELOUR but treated in a real-life setting. We report safety data from the 4th interim analysis in B-pretreated pts. Methods: ASQoP/AFEQT are single-arm, open-label trials of Z in mCRC pts previously treated with an oxaliplatin-containing regimen. Eligible pts receive Z (4 mg/kg) q2w on day 1 of each cycle followed by FOLFIRI until disease progression, unacceptable toxicity, death, or investigator/pt decision. Initial starting doses of FOLFIRI and subsequent modifications are at treating physician’s discretion. % of pts with grade (G) 3 or 4 AEs in the combined B-pretreated safety population of ASQoP/AFEQT is compared with B-pretreated pts in the Z + FOLFIRI arm of VELOUR. Results: At data cutoff, overall safety population comprised 688 pts with ≥1 completed treatment cycle; 343 (49.9%) were B-pretreated. Currently, median number of cycles administered to ASQoP/AFEQT pts is 6; in VELOUR, pts in Z + FOLFIRI arm had a median of 9. Table shows summary of TEAEs in B-pretreated pts. Conclusions: Thisinterim safety analysis of ASQoP/AFEQT in B-pretreated pts identified no new safety signals for Z and a trend toward decreased G3/4 events. The analysis provides additional safety data suggesting an acceptable toxicity profile in a real-life setting. Clinical trial information: NCT01571284.B-pretreated patients receiving Z + FOLFIRI. % pts ASQoP/AFEQT (n=343) VELOURa (n=171) G3 G4 G3 G4 Any TEAE 56.0 16.0 64.9 17.5 Proteinuriab (PT) 2.3 0 1.8 0 Stomatitis (PT) 9.9 0.3 10.5 0 Diarrhea (PT) 15.2 0 18.1 0.6 Infections (SOC) 7.0 1.7 12.9 0.6 Hypertension (PT) 19.2 0 16.4 0 PT, preferred term; SOC, system organ class; aPer eCRF; bBased only on AEs.
Emergency Medicine
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal